Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Cirrhosis | 5 | 2025 | 181 | 0.980 |
Why?
|
| Propensity Score | 2 | 2025 | 190 | 0.850 |
Why?
|
| Spinal Cord Stimulation | 1 | 2024 | 8 | 0.820 |
Why?
|
| Hospital Costs | 1 | 2024 | 126 | 0.800 |
Why?
|
| Spinal Cord Injuries | 1 | 2024 | 54 | 0.780 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2024 | 92 | 0.760 |
Why?
|
| Length of Stay | 2 | 2024 | 828 | 0.730 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2025 | 15 | 0.440 |
Why?
|
| Laparotomy | 1 | 2014 | 54 | 0.420 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 88 | 0.410 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 88 | 0.340 |
Why?
|
| Clinical Enzyme Tests | 1 | 2010 | 13 | 0.330 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 35 | 0.330 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 46 | 0.320 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2010 | 27 | 0.320 |
Why?
|
| Hypertension, Portal | 2 | 2025 | 19 | 0.310 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 70 | 0.310 |
Why?
|
| Liver Failure, Acute | 2 | 2020 | 25 | 0.270 |
Why?
|
| Hospital Mortality | 3 | 2024 | 875 | 0.250 |
Why?
|
| Hepatic Encephalopathy | 2 | 2024 | 10 | 0.240 |
Why?
|
| Incidence | 2 | 2024 | 1419 | 0.240 |
Why?
|
| Propranolol | 1 | 2025 | 22 | 0.240 |
Why?
|
| Liver | 1 | 2010 | 871 | 0.230 |
Why?
|
| Databases, Factual | 3 | 2025 | 883 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2025 | 152 | 0.220 |
Why?
|
| Spinal Cord | 1 | 2024 | 209 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2025 | 6872 | 0.180 |
Why?
|
| Middle Aged | 9 | 2025 | 18273 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 2 | 2014 | 89 | 0.170 |
Why?
|
| Sex Factors | 1 | 2024 | 992 | 0.170 |
Why?
|
| Intracranial Hypertension | 1 | 2020 | 9 | 0.170 |
Why?
|
| Brain Edema | 1 | 2020 | 29 | 0.160 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 6 | 0.140 |
Why?
|
| Male | 9 | 2025 | 31047 | 0.140 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 10 | 0.140 |
Why?
|
| Prognosis | 2 | 2014 | 1784 | 0.130 |
Why?
|
| Female | 9 | 2025 | 34018 | 0.130 |
Why?
|
| Humans | 11 | 2025 | 65140 | 0.130 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2016 | 9 | 0.130 |
Why?
|
| Hospitalization | 1 | 2024 | 1392 | 0.130 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2018 | 78 | 0.120 |
Why?
|
| United States | 3 | 2025 | 8093 | 0.120 |
Why?
|
| Risk Factors | 5 | 2025 | 5429 | 0.120 |
Why?
|
| Bacterial Infections | 2 | 2014 | 150 | 0.120 |
Why?
|
| Adult | 5 | 2024 | 17358 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 308 | 0.110 |
Why?
|
| Survival Rate | 2 | 2014 | 844 | 0.110 |
Why?
|
| Intraoperative Period | 1 | 2014 | 34 | 0.110 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 47 | 0.100 |
Why?
|
| Aged | 4 | 2025 | 14965 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 32 | 0.100 |
Why?
|
| Multiple Organ Failure | 1 | 2014 | 48 | 0.100 |
Why?
|
| Emergencies | 1 | 2014 | 123 | 0.100 |
Why?
|
| Cause of Death | 1 | 2014 | 221 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 333 | 0.100 |
Why?
|
| Boston | 2 | 2011 | 258 | 0.100 |
Why?
|
| Cross Infection | 1 | 2014 | 164 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2483 | 0.090 |
Why?
|
| Cold Ischemia | 1 | 2011 | 3 | 0.090 |
Why?
|
| Death | 1 | 2011 | 33 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2011 | 145 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1559 | 0.080 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 71 | 0.080 |
Why?
|
| ROC Curve | 1 | 2010 | 292 | 0.080 |
Why?
|
| Biopsy | 1 | 2010 | 456 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2011 | 219 | 0.070 |
Why?
|
| Massachusetts | 1 | 2014 | 2145 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 801 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2025 | 5792 | 0.070 |
Why?
|
| Time Factors | 3 | 2025 | 3762 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1163 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1113 | 0.060 |
Why?
|
| Portal Pressure | 1 | 2025 | 3 | 0.060 |
Why?
|
| Biomarkers | 1 | 2010 | 1480 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 1656 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2244 | 0.040 |
Why?
|
| Intracranial Pressure | 1 | 2020 | 19 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2020 | 40 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 162 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 3308 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 21 | 0.030 |
Why?
|
| United Kingdom | 1 | 2018 | 85 | 0.030 |
Why?
|
| Australia | 1 | 2018 | 130 | 0.030 |
Why?
|
| Varicose Veins | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 415 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 78 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 372 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 363 | 0.030 |
Why?
|
| North America | 1 | 2014 | 114 | 0.030 |
Why?
|
| Peritonitis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 1565 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 97 | 0.020 |
Why?
|
| Primary Graft Dysfunction | 1 | 2011 | 5 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2011 | 57 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 413 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 296 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1445 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 576 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 2102 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 4809 | 0.010 |
Why?
|